TY - JOUR
T1 - Statin therapy and inflammation in patients with diabetes treated with high dose aspirin
AU - Chaudhary, Rahul
AU - Bliden, Kevin P.
AU - Garg, Jalaj
AU - Mohammed, Nafees
AU - Tantry, Udaya
AU - Mathew, Denny
AU - Toth, Peter P.
AU - Franzese, Christopher
AU - Gesheff, Martin
AU - Pandya, Shachi
AU - Gurbel, Paul
N1 - Funding Information:
This study was supported by a research grant from Sinai Hospital of Baltimore. Thromboelastography supplies were provided by Haemonetics® Corp. VAP © testing was provided by Atherotech® Inc. Urinary 11-dehydrothromboxane B 2 and AtherOx testing was provided by Corgenix Medical Corp. We wish to acknowledge Tania Gesheff RN, MSN, Kiran Kalra, MBBS, and Cescelle Barbour RN, MSN for their contributions to this study.
Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Background Statin and aspirin form the therapeutic cornerstone in patients with coronary artery disease (CAD) and diabetes. Little is known about relationship of statins with blood thrombogenicity and inflammation in these patients. Methods Two hundred nine consecutive patients with diabetes and suspected CAD undergoing elective cardiac catheterization were divided in groups based on statin treatment in the Multi-Analyte, Thrombogenic, and Genetic Markers Atherosclerosis study. Urinary 11-dehydrothromboxane B2 (11-dh-TxB2), lipid profile and oxLDL/β2GPI were measured by AspirinWorks™ ELISA assay, vertical density gradient ultracentrifugation and immunoassay respectively. Thrombelastography, and ADP- and collagen-induced light transmittance aggregometry assessed thrombogenicity. CAD was classified as none/minor [< 20% diameter stenosis (DS)], moderate (20–75% DS), or severe (> 75% DS). Results Severe, moderate, and no CAD was observed in 66, 19, and 15% of patients respectively. Patients on statins had significantly lower 11-dh-TxB2, collagen-induced aggregation, total cholesterol, total LDL, LDL3, oxidized-LDL, Apo B100, and ApoB100/A1 ratio (p < 0.01 for all). Statin therapy demonstrated a lower proportion of patients with high urinary 11-dh-TxB2 (> 1500 pg 11-dh-TxB2/mg creatinine) (25 vs. 57%, p = 0.01). Conclusion Statins along with aspirin, confers additional anti-inflammatory and antithrombotic effect in diabetics with CAD. Urinary 11-dh-TxB2 may be a useful biomarker for personalizing statin therapy.
AB - Background Statin and aspirin form the therapeutic cornerstone in patients with coronary artery disease (CAD) and diabetes. Little is known about relationship of statins with blood thrombogenicity and inflammation in these patients. Methods Two hundred nine consecutive patients with diabetes and suspected CAD undergoing elective cardiac catheterization were divided in groups based on statin treatment in the Multi-Analyte, Thrombogenic, and Genetic Markers Atherosclerosis study. Urinary 11-dehydrothromboxane B2 (11-dh-TxB2), lipid profile and oxLDL/β2GPI were measured by AspirinWorks™ ELISA assay, vertical density gradient ultracentrifugation and immunoassay respectively. Thrombelastography, and ADP- and collagen-induced light transmittance aggregometry assessed thrombogenicity. CAD was classified as none/minor [< 20% diameter stenosis (DS)], moderate (20–75% DS), or severe (> 75% DS). Results Severe, moderate, and no CAD was observed in 66, 19, and 15% of patients respectively. Patients on statins had significantly lower 11-dh-TxB2, collagen-induced aggregation, total cholesterol, total LDL, LDL3, oxidized-LDL, Apo B100, and ApoB100/A1 ratio (p < 0.01 for all). Statin therapy demonstrated a lower proportion of patients with high urinary 11-dh-TxB2 (> 1500 pg 11-dh-TxB2/mg creatinine) (25 vs. 57%, p = 0.01). Conclusion Statins along with aspirin, confers additional anti-inflammatory and antithrombotic effect in diabetics with CAD. Urinary 11-dh-TxB2 may be a useful biomarker for personalizing statin therapy.
KW - 11-Dehydrothromboxane B2
KW - CAD
KW - Diabetes
KW - Inflammation
KW - Statin
UR - http://www.scopus.com/inward/record.url?scp=84969929975&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969929975&partnerID=8YFLogxK
U2 - 10.1016/j.jdiacomp.2016.05.002
DO - 10.1016/j.jdiacomp.2016.05.002
M3 - Article
C2 - 27237049
AN - SCOPUS:84969929975
SN - 1056-8727
VL - 30
SP - 1365
EP - 1370
JO - Journal of Diabetes and its Complications
JF - Journal of Diabetes and its Complications
IS - 7
ER -